Continuing concerns over imported pharmaceuticals: hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, first session, June 7, 2001, Volume 4
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
50 dosage units active ingredient addictive agencies Americans APIs border bulk Burr ceutical Chairman committee companies consumers controlled substances counterfeit drugs counterfeit pharmaceuticals counterfeit products criminal dangerous declared DeGette Deutsch diazepam Dingell diversion drug abuse Drug Enforcement Administration drug importation drug products enforcement entering the U.S. FDA approved FDA's Federal Food and Drug foreign GlaxoSmithKline Greenwood hearing Hubbard illegal importation of controlled inspectors international mail Internet pharmacies investigations issue labels Laredo legitimate look mail facilities manufactured Mexican Mexico Nagel Novartis Nuevo Laredo ONDCP Oxycodone Oxycontin packages parcels patients percent personal importation personal medical phar pharma pharmaceutical diversion pharmaceutical products pills Prepared Statement prescription drugs problem public health purchased question regulation regulatory reimportation require risk Rode Rohypnol safety Shepherd shipments Stupak Subcommittee tablets testimony Texas Tijuana tion Trundley U.S. citizens U.S. Customs Service U.S. residents unapproved